Acromegaly

Overview

Acromegaly is a rare, long-term hormonal disorder in which excessive growth hormone (GH), usually from a noncancerous GH-secreting pituitary tumor, raises insulin-like growth factor 1 (IGF-1) and gradually enlarges bones, soft tissues, and internal organs. It is typically diagnosed in adulthood and can cause changes in facial features and extremities, headaches, sweating, joint disease, sleep apnea, diabetes, heart disease, and vision problems when the tumor presses on nearby structures. NIDDK overview 2024 diagnostic and remission consensus

The goal of care is remission: normalization of age-adjusted IGF-1, control of GH excess, relief of tumor pressure, and prevention or treatment of complications. Transsphenoidal surgery to remove the pituitary tumor is generally the first-line treatment and can be curative; persistent, recurrent, invasive, or inoperable disease is treated with somatostatin receptor ligands, the GH-receptor blocker pegvisomant, cabergoline in selected cases, and sometimes radiotherapy. Expert follow-up combines symptoms, hormone testing, and pituitary MRI because biochemical control does not by itself prove that all residual tumor risk has ended. French national protocol 2024 diagnostic and remission consensus

Scope of Recent Research (2020–present)

Research since 2020 has been active, but it is aimed predominantly at making long-term disease control more effective, individualized, and less burdensome rather than at creating a new biological cure. The dominant questions are how to replace frequent clinic-administered injections with oral, self-administered, or longer-acting therapies; how to identify tumors likely to respond to a particular drug; and how to treat patients whose GH and IGF-1 remain uncontrolled after surgery. As of October 7, 2026, no gene therapy, gene-editing, RNA therapy, or cell therapy has established clinical evidence of curing acromegaly; durable cure still depends mainly on complete tumor removal or, more slowly and less predictably, tumor-directed radiotherapy. 2026 pharmacotherapy review 2024 diagnostic and remission consensus

Major Breakthroughs and Emerging Therapies

The clearest recent advance is paltusotine (Palsonify), a once-daily oral, nonpeptide drug that activates somatostatin receptor subtype 2 (SSTR2), the principal receptor used to suppress GH secretion in many somatotroph tumors. The U.S. Food and Drug Administration approved it on September 25, 2025, for adults with inadequate response to surgery or for whom surgery is not appropriate. In two placebo-controlled phase 3 studies, 56% of 111 participants with active disease achieved normal IGF-1 at 24 weeks versus 5% on placebo, while 83% of 58 participants previously controlled on injectable therapy maintained biochemical control at 36 weeks versus 4% on placebo. This is an important access and treatment-burden advance, but it suppresses tumor hormone output rather than eliminating the tumor and therefore is not a cure. FDA approval announcement PATHFNDR-1 phase 3 study

A second strategy is improved delivery of established somatostatin drugs. Oral octreotide capsules demonstrated noninferiority to injectable octreotide or lanreotide for maintaining biochemical response in a phase 3 randomized trial: 91% of oral-octreotide recipients and 100% of injectable-treatment recipients maintained response during the randomized phase. Oral octreotide phase 3 trial CAM2029/Oczyesa, a room-temperature, self-administered subcutaneous octreotide depot using FluidCrystal delivery technology, maintained normal IGF-1 in 72.2% of treated participants versus 37.5% on placebo in the ACROINNOVA 1 phase 3 trial, with improved quality-of-life measures relative to baseline standard care. ACROINNOVA 1 phase 3 trial These formulations may make treatment more acceptable and consistent, but, like existing somatostatin medicines, they generally require ongoing use.

Longer dosing intervals are also moving forward. Debio 4126 is a sustained-release octreotide formulation designed for dosing every 12 weeks rather than every 4 weeks. Debiopharm initiated the randomized phase 3 OXTEND-03 study in December 2025 to test whether people already controlled on somatostatin analogues can maintain biochemical control with quarterly treatment; the planned global study aims to enroll about 120 participants. OXTEND-03 trial announcement This is a convenience innovation, not a tumor-eradicating intervention.

The most cure-relevant laboratory work is moving toward precision tumor therapy. A 2022 proteogenomic study of 121 GH-producing pituitary tumors found that molecular features including GNAS status, SSTR2/SSTR5 biology, ATP2A2, ARID5B, WWC3, SERINC1, and ZFAND3 correlated with hormone or tumor-volume responses to somatostatin treatment. Proteogenomic landscape of GH-producing tumors Separately, an experimental SSTR5-preferring molecule, HTL0030310, reduced hormone secretion in cultured human GH-secreting pituitary tumors, supporting receptor-tailored drugs for tumors that respond poorly to conventional SSTR2-focused therapy. HTL0030310 human-tumor study These findings are preclinical or early translational signals rather than evidence of a cure.

Clinical Trials and Experimental Approaches

Crinetics Pharmaceuticals sponsored the pivotal PATHFNDR paltusotine program. PATHFNDR-1 was a randomized, double-blind phase 3 withdrawal study in 58 adults controlled on depot octreotide or lanreotide; 25 of 30 participants receiving paltusotine maintained normal IGF-1 at 36 weeks, compared with 1 of 28 receiving placebo. PATHFNDR-1 phase 3 study PATHFNDR-2 enrolled 111 adults with untreated or washed-out active disease; the FDA’s review reported normal IGF-1 at week 24 in 56% on paltusotine versus 5% on placebo. FDA approval announcement

Camurus AB sponsored ACROINNOVA 1 (NCT04076462), a completed multinational, randomized, placebo-controlled phase 3 trial of CAM2029 in 72 adults previously controlled on monthly octreotide LAR or lanreotide. CAM2029 achieved the primary endpoint of normal IGF-1 at weeks 22 and 24 in 72.2% of participants versus 37.5% with placebo; an open-label phase 3 follow-on study, ACROINNOVA 2, has evaluated longer-term safety, symptom control, and biochemical control. ACROINNOVA 1 registry record ACROINNOVA 1 phase 3 trial

Debiopharm’s OXTEND-03 trial (NCT06930625) is a phase 3, multicenter, randomized trial of quarterly Debio 4126 in adults previously treated with somatostatin analogues. OXTEND-03 ClinicalTrials.gov record Other experimental programs described in recent reviews include alternative somatostatin ligands, GH-neutralizing antibodies, and next-generation GH-receptor antagonists, but none has yet demonstrated that it can permanently eradicate a GH-secreting pituitary tumor in people. 2026 pharmacotherapy review

Methodologies and Scientific Approaches

Modern acromegaly trials generally assess biochemical control with age-adjusted IGF-1, often alongside repeated GH measurements, symptom diaries, quality-of-life instruments, safety monitoring, and pituitary MRI. The 2024 international consensus emphasizes that clinicians should interpret hormone results alongside symptoms, comorbidities, imaging, and evidence of residual or recurrent tumor rather than relying on one laboratory measurement alone. 2024 diagnostic and remission consensus

For discovery research, investigators analyze surgically removed human tumors using targeted DNA sequencing, RNA sequencing, proteomics, receptor immunostaining, and short-term ex vivo drug-exposure experiments. The 2022 proteogenomic study linked tumor molecular profiles to octreotide hormone-response and tumor-volume-response measures, while the HTL0030310 study incubated fresh human GH-secreting tumors with a candidate receptor ligand and measured subsequent hormone secretion and receptor expression. Proteogenomic landscape of GH-producing tumors HTL0030310 human-tumor study

Leading Institutions and Funding

Clinical leadership is concentrated in multidisciplinary pituitary centers, including Massachusetts General Hospital and Harvard Medical School, Oregon Health & Science University, Cedars-Sinai Medical Center, Charité–Universitätsmedizin Berlin, Erasmus University Medical Center, and hospitals affiliated with the Acromegaly Consensus Group. These centers provide the endocrine, neurosurgical, pathology, radiology, and clinical-trial expertise required for a rare disease in which treatment decisions often depend on tumor anatomy and hormone response. 2024 diagnostic and remission consensus

Industry funding has driven the largest recent therapeutic trials: Crinetics Pharmaceuticals developed paltusotine, Camurus AB sponsored ACROINNOVA studies of CAM2029, and Debiopharm is sponsoring OXTEND-03 of Debio 4126. FDA drug-trials snapshot for Palsonify ACROINNOVA 1 registry record OXTEND-03 trial announcement Publicly supported foundational work is also important: the U.S. National Institutes of Health, through NICHD programs and the NIH Clinical Center, supports studies of pituitary-tumor genetics, molecular mechanisms, animal models, tissue collection, imaging, and clinical characterization. NICHD pituitary-tumor research program NIH Clinical Center pituitary-tumor protocol

Strengths, Limitations, and Challenges

The major strength of the 2020–2026 pipeline is that it gives more patients practical ways to achieve or maintain biochemical control: oral paltusotine, oral octreotide, self-administered CAM2029, and prospective quarterly octreotide could reduce injection burden and improve adherence. FDA approval announcement Oral octreotide phase 3 trial ACROINNOVA 1 phase 3 trial However, these advances principally manage GH secretion; they do not reliably remove residual tumor, eliminate the need for surveillance, or guarantee lifelong remission after therapy is stopped. 2024 diagnostic and remission consensus

Important limitations remain. Drug response varies substantially among tumors, invasive tumors may not be surgically removable, and the most effective regimen may require combinations that are expensive and difficult to access. Somatostatin-pathway therapies can also cause gastrointestinal effects, gallstones, glucose abnormalities, thyroid changes, slowed heart rate, and nutrient-malabsorption concerns, as reflected in the paltusotine label. FDA approval announcement Molecular biomarkers are promising but have not yet been prospectively validated to select treatment in routine care. Proteogenomic landscape of GH-producing tumors

Outlook and Future Directions

A true broadly applicable biological cure is not close: the field has not yet shown that it can selectively eradicate GH-secreting pituitary tumor cells with gene, RNA, cell, or targeted-drug therapy while preserving normal pituitary function. The nearer-term milestones are wider real-world experience with paltusotine, publication of long-term CAM2029 outcomes, results from the Debio 4126 OXTEND-03 trial, and prospective studies testing whether tumor receptor and molecular profiles can guide the first treatment choice. If precision profiling can identify which tumors will respond to surgery, SSTR2- versus SSTR5-directed drugs, GH-receptor blockade, or combination therapy, it could improve remission rates and reduce years of trial-and-error treatment—even though that would still be personalized control rather than a definitive cure. 2026 pharmacotherapy review Proteogenomic landscape of GH-producing tumors

References

• NIDDK overview — National Institute of Diabetes and Digestive and Kidney Diseases, 2020.
• 2024 diagnostic and remission consensus — Giustina et al., 2024.
• French national protocol — Chanson et al., 2023.
• 2026 pharmacotherapy review — Tritos and Biller, 2026.
• FDA approval announcement — U.S. Food and Drug Administration, 2025.
• PATHFNDR-1 phase 3 study — Biller et al., 2024.
• Oral octreotide phase 3 trial — Samson et al., 2022.
• ACROINNOVA 1 phase 3 trial — Fleseriu et al., 2024.
• OXTEND-03 trial announcement — Debiopharm, 2025.
• Proteogenomic landscape of GH-producing tumors — Yamato et al., 2022.
• HTL0030310 human-tumor study — Fleseriu et al., 2024.
• ACROINNOVA 1 registry record — ClinicalTrials.gov, 2024.
• OXTEND-03 ClinicalTrials.gov record — ClinicalTrials.gov, 2025.
• FDA drug-trials snapshot for Palsonify — U.S. Food and Drug Administration, 2025.
• NICHD pituitary-tumor research program — Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2025.
• NIH Clinical Center pituitary-tumor protocol — National Institutes of Health Clinical Center, 2026.